As community oncology evolves to deliver chimeric antigen receptor (CAR) T and bispecific therapies closer to home, support is needed to ensure patient access and precision medicine capabilities, says Nini Wu, MD.
Navista
Latest Content
While artificial intelligence (AI) is transforming community oncology, Nini Wu, MD, of Navista, emphasizes that success depends on patient access and infrastructure.
Advertisement
Advertisement
Trending on AJMC
1
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
2
Value-Based Care Interventions and Management of CKD Progression
3
New Partnership Model Boosts Maternal Outcomes in Medicaid ACOs
4
CDC Reports Largest Pediatric Influenza-Associated Encephalopathy Case Series in 2024-2025 Season
5
